Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

被引：44
作者：
van de Kerkhove, MP
Di Florio, E
Scuderi, V
Mancini, A
Belli, A
Bracco, A
Scala, D
Scala, S
Zeuli, L
Di Nicuolo, G
Amoroso, P
Calise, F
Chamuleau, RAFM
机构：
[1] Acad Med Ctr, Surg Lab, NL-1105 AZ Amsterdam, Netherlands
[2] Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands
[3] Acad Med Ctr, Dept Hepatol, NL-1105 AZ Amsterdam, Netherlands
[4] D Cotugno Hosp, Virol Lab, Naples, Italy
[5] D Cotugno Hosp, Div Infect Dis 11, Naples, Italy
来源：
CELL TRANSPLANTATION | 2003年 / 12卷 / 06期
关键词：
acute liver failure; bioartificial liver; hepatocyte; transplantation; human; porcine; clinical trial;
D O I：
10.3727/000000003108747163
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 X 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 It by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.
引用
收藏
页码：563 / 568
页数：6
相关论文
共 24 条
[1]   Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study [J].
Adam, R ;
Cailliez, V ;
Majno, P ;
Karam, V ;
McMaster, P ;
Calne, RY ;
O'Grady, J ;
Pichlmayr, R ;
Neuhaus, P ;
Otte, JB ;
Hoeckerstedt, K ;
Bismuth, H .
LANCET, 2000, 356 (9230) :621-627
[2]  
Bernuau J, 1991, OXFORD TXB CLIN HEPA, P923
[3]   The importance of orthotopic liver transplantation in acute hepatic failure [J].
de Rave, S ;
Tilanus, HW ;
van der Linden, J ;
de Man, RA ;
van der Berg, B ;
Hop, WCJ ;
Ijzermans, JNM ;
Zondervan, PE ;
Metselaar, HJ .
TRANSPLANT INTERNATIONAL, 2002, 15 (01) :29-33
[4]  
Donini A, 2000, AM J GASTROENTEROL, V95, P1102
[5]   Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure [J].
Ellis, AJ ;
Hughes, RD ;
Wendon, JA ;
Dunne, J ;
Langley, PG ;
Kelly, JH ;
Gislason, GT ;
Sussman, NL ;
Williams, R .
HEPATOLOGY, 1996, 24 (06) :1446-1451
[6]   In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates [J].
Flendrig, LM ;
laSoe, JW ;
Jorning, GGA ;
Steenbeek, A ;
Karlsen, OT ;
Bovee, WMMJ ;
Ladiges, NCJJ ;
teVelde, AA ;
Chamuleau, RAFM .
JOURNAL OF HEPATOLOGY, 1997, 26 (06) :1379-1392
[7]   Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver [J].
Flendrig, LM ;
Calise, F ;
Di Florio, E ;
Mancini, A ;
Ceriello, A ;
Santaniello, W ;
Mezza, E ;
Sicoli, F ;
Belleza, G ;
Bracco, A ;
Cozzolino, S ;
Scala, D ;
Mazzone, M ;
Fattore, M ;
Gonzales, E ;
Chamuleau, RAFM .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1999, 22 (10) :701-709
[8]   Evaluation of a novel bioartificial liver in rats with complete liver ischemia:: treatment efficacy and species-specific α-GST detection to monitor hepatocyte viability [J].
Flendrig, LM ;
Chamuleau, RAFM ;
Maas, MAW ;
Daalhuisen, J ;
Hasset, B ;
Kilty, CG ;
Doyle, S ;
Ladiges, NCJJ ;
Jörning, GGA ;
la Soe, JW ;
Sommeijer, D ;
te Velde, AA .
JOURNAL OF HEPATOLOGY, 1999, 30 (02) :311-320
[9]   Monitoring xenotransplant recipients for infection by PERV [J].
Herring, C ;
Cunningham, DA ;
Whittam, AJ ;
Fernández-Suárez, XM ;
Langford, GA .
CLINICAL BIOCHEMISTRY, 2001, 34 (01) :23-27
[10]  
Hui T, 2001, J Hepatobiliary Pancreat Surg, V8, P1
123